Neurogene (NGNE) Net Cash Flow (2013 - 2026)

Neurogene has reported Net Cash Flow for 14 years, with the latest figure at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 130.9% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $53.4 million (up 167.26% YoY), and the FY2025 full-year result was -$32.8 million, down 177.86% from the prior year.
• Net Cash Flow for Q1 2026 stood at $20.3 million, down from $32.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $113.6 million in Q4 2022, with the low at -$65.8 million in Q1 2025.
• Historically, Net Cash Flow has averaged $3.2 million across 5 years, with a median of -$12.0 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow surged 1012.01% — and 2025, when it plunged 3837.37%.
• Neurogene's Net Cash Flow stood at $113.6 million in 2022, then retreated by 9.16% to $103.2 million in 2023, then plunged by 32.22% to $70.0 million in 2024, then sank by 53.16% to $32.8 million in 2025, then plunged by 37.94% to $20.3 million in 2026.
• The last three Net Cash Flow figures came in at $20.3 million (Q1 2026), $32.8 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.